CD34+ cells in the blood of patients with multiple myeloma express CD19 and IgH mRNA and have patient-specific IgH VDJ gene rearrangements

Blood

Volumn 89, Issue 5, 1997, Pages 1824-1833

  Szczepek, Agnieszka J ^b   Bergsagel, P L ^b   Axelsson, Linus ^b   Brown, Christopher B ^b   Belch, Andrew R ^b   Pilarski, Linda M ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD34 ANTIGEN;

ARTICLE; B LYMPHOCYTE; CANCER INFILTRATION; CONTROLLED STUDY; GENE REARRANGEMENT; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; PLASMA CELL; PRIORITY JOURNAL;

EID: 0031036891     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.5.1824     Document Type: Article

References (40)

1. Durie BGM, Salmon SS: Staging, kinetics, and flow cytometry of multiple myeloma, in Wiernik P, Canellos G, Kyle R, Schiffer C (eds): Neoplastic Diseases of the Blood (vol 2). New York, NY, Churchill Livingstone, 1985, p 513
2. Hulin N, Conte PF, Pileri A: Biology of the human myeloma cell population. II. Cytokinetic characteristics. Clin Lab 8:49, 1978
3. Barlogie B, Epstein J, Selvanayagam P, Alexanian R: Plasma cell myeloma - New biological insights and advances in therapy. Blood 73:865, 1989
4. Caligaris-Cappio F, Bergui L, Tesio L, Pizzolo G, Malavasi F, Chilosi M, Campana D, van Camp B, Janossy G: Identification of malignant plasma cell precursors in the bone marrow of multiple myeloma. J Clin Invest 76:1243, 1985
5. Pilarski LM, Mant MM, Belch AR: Circulating, monoclonal, multi-drug resistant B cells may comprise the malignant stem cells population in multiple myeloma, in Dammaco F, Barlogie B (eds): Challenges in Modern Medicine (vol 4). 1994, p 31
6. Pilarski LM, Jensen GS: Monoclonal circulating B cells in multiple myeloma: A continuously differentiating possibly invasive population as defined by expression of CD45 isoforms and adhesion molecules. Hematol Oncol Clin North Am 6:297, 1992
7. Bergsagel PL, Masellis Smith A, Szczepek A, Mant MJ, Belch AR, Pilarski LM: In multiple myeloma, clonotypic B lymphocytes are detectable among CD 19+ peripheral blood cells expressing CD38, CD56 and monotypic immunoglobulin light chain. Blood 85:436, 1995
8. Pilarski LM, Masellis Smith A, Szczepek A, Mant MJ, Belch AR: Circulating clonotypic B cells in the biology of myeloma. Speculations on the origin of multiple myeloma. Leuk Lymphoma 22:375, 1996
9. Pilarski LM, Szczepek A, MacDonald H, Mant MJ, Belch AR: Single cell IgH CDR3 and in situ RT-PCR for IgH CDR3 and Ig light chain unequivocally confirm that circulating CD 19+ cells in multiple myeloma are B cells. Blood 86:58a, 1995 (abstr, suppl 1)
10. Szczepek AJ, Mant MJ, Belch AR, Pilarski LM: Circulating B cells share clonotypic IgH VDJ rearrangements with bone marrow plasma cells in multiple myeloma: Quantitative enumeration by patient-specific amplification in single cell RT-PCR, and in situ RT-PCR. (submitted)
11. Szczepek AJ, Masselis Smith A, Mant MJ, Belch AR, Pilanski LM: Expression of CD34 and clonotypic IgH rearrangements by DNA hyperdiploid B cells disinguishes them from polyclonal diploid B cells in the blood of patients with multiple myeloma. (submitted)
12. Pilarski LM, Belch AJ: Circulating monoclonal B cells expressing p-glycoprotein may be a reservoir of multidrug resistant disease in multiple myeloma. Blood 83:724, 1994
13. Bergsagel PL, Belch AR, Pilarski LM: The blood B cells and bone marrow plasma cells in a patient with multiple myeloma include cells with the same N-ras mutation. Blood 84:524a, 1994 (abstr, suppl 1)
14. Jensen GS, Belch AR, Kherani F, Mant MJ, Ruether BA, Pilarski LM: Restricted expression of immunoglobulin light chain mRNA and of the adhesion molecule CD1 1b on circulating monoclonal B lineage cells in peripheral blood of myeloma patients. Scand J Immunol 36:843, 1992
15. Pilarski LM, Masellis Smith A, Belch AR, Yang B, Savani RC, Turley EA: RHAMM, a receptor for hyaluronan-mediated molility, on normal lymphocytes, thymocytes and in B cell malignancy: A mediator in B cell malignancy? Leuk Lymphoma 14:363, 1994
16. Masellis-Smith A, Belch AR, Mant MJ, Turley EA, Pilarski LM: Hyaluronan-dependent motility of B cells and leukemic plasma cells but not of bone marrow plasma cells in multiple myeloma: Alternate usage of RHAMM and CD44. Blood 87:1891, 1996
17. Jensen GS, Belch AR, Mant MJ, Ruether BA, Yacyshyn BR, Pilarski LM: Expression of multiple beta-1 integrins on circulating monoclonal B cells in patients with multiple myeloma. Am J Hematol 43:29, 1992
18. Pilarski LM, Cass CE, Tsuruo T, Belch AR: Multidrug resistance of a continuously differentiating monoclonal B lineage in the blood and bone marrow of patients with multiple myeloma. Curr Top Microbiol Immunol 182:177, 1992
19. Pilarski LM, Belch AR: Intrinsic expression of the multidrug transporter, P-glycoprotein 170, in multiple myeloma; implications for treatment. Leuk Lymphoma 17:367, 1995
20. Salmon SE, Dalton WS, Grogan TM, Plezia P, Lehnert M, Roe DJ, Miller TP: Multidrug-resistant myeloma: Laboratory and clinical effects of verapamil as a chemosensitizer. Blood 78:44, 1991
21. Dalton WS, Grogan TM, Meltzer PS, Scheper RJ, Durie BGM, Taylor CW, Miller TP, Salmon SE: Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: Detection of p-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 7:415, 1989
22. Simmons DL, Satterthwaite AB, Tenen DG, Seed B: Molecular cloning of a cDNA encoding CD34, a sialomucin of human hematopoietic stem cells. J Immunol 148:267, 1992
23. Baumhueter S, Singer MS, Henzel W, Hemmerich S, Renz M, Rosen SD, Lasky LA: Binding of L-selectin to the vascular sialomucin CD34. Science 262:436, 1993
24. Traore Y, Hirn J: Certain anti-CD34 monoclonal antibodies induce homotypic adhesion of leukemic cell lines in a CD18-dependent and a CD18-independent way. Eur J Immunol 24:2304, 1994
25. Healy L, May G, Gale K, Grosveld F, Greaves M, Enver T: The stem cell antigen CD34 functions as a regulator of hematopoietic cell adhesion. Proc Natl Acad Sci USA 92:12240, 1995
26. Sutherland HJ, Eaves CJ, Eaves AC, Dragowska W, Lansdorp PM: Characterization and partial purification of human marrow cells capable of initiating long-term hematopoiesis in vitro. Blood 74:1563, 1989
27. Sutherland R, Keating A: The CD34 antigen: Structure, biology and potential clinical applications. J Hematother 1:115, 1992
28. Vescio RA, Hong CH, Cao J, Kim A, Schiller GJ, Lichtenstein AK, Berenson RJ, Berenson JR: The hematopoietic stem cell antigen CD34 is not expressed on the malignant cells in multiple myeloma. Blood 84:3283, 1994
29. Zola H, Mcardle PJ, Bradford T, Weedon H, Yasui H, Kurosawa Y: Preparation and characterization of a chimeric CD 19 monoclonal antibody. Immunol Cell Biol 69:411, 1991
30. Pietersz GA, Li WJ, Sutton VR, Burgess J, McKenzie IFC, Zola H, Trapani JA: In vitro and in vivo antitumor-activity of a chimeric anti-CD19 antibody. Cancer Immunol Immunother 41:53, 1995
31. Nuovo G: PCR In Situ Hybridization. New York, NY, Raven, 1994
32. Nuovo GJ, Forde A: An improved system for reverse transcriptase in situ PCR. J Histotechnol 18:295, 1995
33. Boshoff C, Schulz TF, Kennedy MM, Graham AK, Fisher C, Thomas A, McGee JO, O'Leary JJ: Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells. Nat Med 1:1274, 1995
34. Owen RG, Child JA, Rawson A, Smith GM, Johnson R, Woodhead V, Elsworth A, Morgan GJ: Detection of contaminating cells in PBPC harvests and the efficacy of CD34 selection in patients with multiple myeloma. Blood 84:352a, 1994 (abstr, suppl 1)
35. Schiller G, Vesico R, Freytas C, Spitzer G, Sahebi F, Lee M, Wu CH, Cao J, Lee JC, Hong CH, Lichtenstein A, Lill A, Hall J, Berenson R, Berenson J: Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advance multiple myeloma. Blood 86:390, 1995
36. Dreyfus F, Ribrag V, Leblond V, Ravaud P, Melle J, Quarre MC, Pillier C, Boccaccio C: Detection of malignant B cells in peripheral blood stem cell collections after chemotherapy in patients with multiple myeloma. Bone Marrow Transplant 15:707, 1995
37. Gazitt Y, Reading CC, Hoffman R, Wickrema A, Vesole D, Jagannath S, Condino J, Lee B, Barlogie B, Tricot G: Purified CD34+ Lin-Thy+ stem cells do not contain clonal myeloma cells. Blood 86:381, 1995
38. Mayani H, Lansdorp P: Thy-1 expression is linked to functional properties of primitive hematopoietic progenitor cells from human umbilical cord blood. Blood 83:2410, 1994
39. Jensen GS, Mant MJ, Belch AJ, Berensen JR, Ruether BA, Pilarski LM: Selective expression of CD45 isoforms defines CALLA+ monoclonal B lineage cells in peripheral blood from myeloma patients as late stage B cells. Blood 78:711, 1991
40. Majdic O, Stockl J, Pickl WF, Bohuslav J, Strobl H, Scheinecker C, Stockinger H, Knapp W: Signalling and induction of enhanced cytoadhesiveness via the hematopoietic progenitor cell surface molecule CD34. Blood 83:1226, 1994